Latest study proves that particular dose of new drug named "VEGF Trap-Eye" on an as-needed basis can cure devastating ocular diseases.
This was concluded by undergoing a phase-two study done by Bayer Healthcare AG and Regeneron Pharmaceuticals. The trail involve patients suffering from wet age-related Macular degeneration who were provided with medicine VEGF Trap-Eye as-needed basis.
The results when taken out after 52 weeks showed highly significant improvements in the retinal thickness and vision gain.
This VEGF Trap-Eye has a strong potential to fulfil a significant unmet medical need in eye treatment, says Dr George Yancopoulos, President of Regeneron Research Laboratories.
Source: https://www.hayspharma.com/
Filed under Eye Care Products, Eye Treatment, Macular Degeneration, macula degeneration | Tags: eye, George, Macular Degeneration, Phase two trail, VEGF Trap-Eye | Comment Below
Related?
VEGF Trap-Eye Phase 2 trial reports significant improvement in neovascular diseaseSeptember 30th, 2008 Regeneron Pharmaceuticals, Inc and Bayer HealthCare AG has announced the result of Phase 2 trial of the VEGF Trap-Eye. It reported to have achieved durable improvements in visual acuity and in biologic measures of neovascular disease, including retinal thickness and active choroidal neovascularization lesion size.
Bayer and Regenron Agreed to Jointly Develop Treatment for Eye DiseaseOctober 23rd, 2006 Bayer AG's Bayer Healthcare unit and Regeneron Pharmaceuticals Inc. agreed to jointly develop, and commercialize a treatment for eye disease.
Scripps Institute Researchers Offer New Drug For Vision LossMay 24th, 2008 A new study was approached by Martin Friedlander and colleagues, at the Scripps Institute, La Jolla, suggesting a simpler way to reduce VEGF induced blood vessel in the eye which causes vision loss. In most disease, vision loss is caused, when the permeability of blood vessels in the retina of eye is alerted by other factors (e.g, fluid accumulating in the retina impairing eyesight).
American Academy and SOE to discuss Retinopathy of prematurity problemNovember 12th, 2008 Retinopathy of prematurity is a disease of the eye that affects prematurely born babies. It is thought to be caused by disorganized growth of retinal blood vessels which may result in scarring and retinal detachment.
Combination Antibiotic-Steroid for Ocular Inflammation Filed for FDA ApprovalJuly 8th, 2006 ISTA Pharmaceuticals Inc., which develops eye-care treatments said Thursday it filed a new drug application with the U.S. Food and Drug Administration for its combination antibiotic steroid to fight ocular inflammation.
Homeopathy is Proved to be Very Much Effective in Eye DiseasesJune 26th, 2007 Dr Upendra Shaha has cured various eye diseases of numerous people suffering for long in spite of several efforts made by the different doctors from Nepal and India. Dr Shaha said if an eye patient suffering for a long time takes homeopathic medicine, he will regain his normal eyesight without using eye glasses.
Scientist shall present study results of Epidemic Kerato-Conjunctivitis (EKC) drug at Diseases and Drug Discovery conferenceApril 21st, 2009 The studies on nanoviricide drug candidates against Epidemic Kerato-Conjunctivitis (EKC) were conducted at the Feinstein Institute for Medical Research of the NSLIJ. Dr. Boniuk will be speaking at the GTC-Bio Conference on Ocular Diseases and Drug Discovery on April 21 in Philadelphia, PA.
Midwest Eye Institute Doctor Helps To Test Drug For Macular Degeneration June 8th, 2008 The Macular degeneration is the type of eye disease that develops in the older people. It is one of the major causes of vision loss in countries like the USA, especially among the age group of 65 and above.
